{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:39:02Z","timestamp":1760729942709,"version":"3.44.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1176\/appi.psy.49.3.258","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T13:39:47Z","timestamp":1209562787000},"page":"258-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Preliminary Attempt to Personalize Risperidone Dosing Using Drug\u2013Drug Interactions and Genetics: Part I"],"prefix":"10.1016","volume":"49","author":[{"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil B.","family":"Sandson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L.","family":"Cozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1176\/appi.psy.49.3.258_bib0005","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/jama.286.18.2289","article-title":"The anatomy of the human genome: a neo-vesalian basis for medicine in the 21st century","volume":"286","author":"McKusick","year":"2001","journal-title":"JAMA"},{"key":"10.1176\/appi.psy.49.3.258_bib0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature05329","article-title":"Global variation in copy number in the human genome","volume":"444","author":"Redon","year":"2006","journal-title":"Nature"},{"key":"10.1176\/appi.psy.49.3.258_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.277.5324.393","article-title":"Massively parallel genomics","volume":"277","author":"Fodor","year":"1997","journal-title":"Science"},{"key":"10.1176\/appi.psy.49.3.258_bib0020","first-page":"2039","article-title":"New research horizons","volume":"278","year":"1997","journal-title":"Science"},{"key":"10.1176\/appi.psy.49.3.258_bib0025","first-page":"68","article-title":"Deciphering the code and what might come from it","volume":"8","author":"Lertola","year":"1999","journal-title":"Time"},{"key":"10.1176\/appi.psy.49.3.258_bib0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jama.285.5.540","article-title":"Implications of the human genome project for medical science","volume":"285","author":"Collins","year":"2001","journal-title":"JAMA"},{"key":"10.1176\/appi.psy.49.3.258_bib0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19","volume":"47","author":"de Leon","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1176\/appi.psy.49.3.258_bib0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JCP.0b013e318058244d","article-title":"The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultra-rapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19","volume":"27","author":"de Leon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0050","first-page":"236","article-title":"A message from the Titanic","volume":"4","author":"Preskorn","year":"1998","journal-title":"J Pract Psychiatry Behav Health"},{"key":"10.1176\/appi.psy.49.3.258_bib0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of the last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0060","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.0001-690X.2003.00238.x","article-title":"Patterns of risperidone prescription: a utilization study in southwest France","volume":"109","author":"Martin","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"10.1176\/appi.psy.49.3.258_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4088\/JCP.v62n0411","article-title":"Optimal dosing with risperidone: updated recommendations","volume":"62","author":"Williams","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0075","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0080","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0006-3223(01)01256-2","article-title":"Broad therapeutic uses of atypical antipsychotic medications","volume":"50","author":"Buckley","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0085","series-title":"Comparative Effectiveness Review No. 6","article-title":"Comparative effectiveness of off-label use of atypical antipsychotics","author":"Shekelle","year":"2007"},{"key":"10.1176\/appi.psy.49.3.258_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31802e5126","article-title":"Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002","volume":"27","author":"Reist","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0100","first-page":"194","article-title":"A Canadian multicenter, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients","volume":"17","author":"Chouinard","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0105","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00023210-200115090-00001","article-title":"Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies","volume":"15","author":"Tauscher","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1176\/appi.psy.49.3.258_bib0115","first-page":"719","article-title":"Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications","volume":"31","author":"Carter","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"10.1176\/appi.psy.49.3.258_bib0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0447.1999.tb00972.x","article-title":"A combined analysis of double-blind studies of risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms","volume":"99","author":"Lemmens","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"10.1176\/appi.psy.49.3.258_bib0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00004714-199706000-00010","article-title":"Extrapyramidal symptoms in patients treated with risperidone","volume":"17","author":"Simpson","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002280100302","article-title":"Antipsychotic-induced extrapyramidal syndromes: risperidone compared with lowand high-potency conventional antipsychotic drugs","volume":"57","author":"Schillevoort","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00023210-200418090-00005","article-title":"Dose response and atypical antipsychotics in schizophrenia","volume":"18","author":"Kinon","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1176\/appi.psy.49.3.258_bib0140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrg1432","article-title":"Pharmacogenetics and drug development: the path to safer and more effective drugs","volume":"5","author":"Roses","year":"2004","journal-title":"Nat Rev"},{"key":"10.1176\/appi.psy.49.3.258_bib0145","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2007.05.020","volume":"96","author":"de Leon","year":"2007","journal-title":"Schizophr Res"},{"issue":"suppl 11","key":"10.1176\/appi.psy.49.3.258_bib0155","first-page":"4","article-title":"Preclinical pharmacology of neuroleptics: focus on new-generation compounds","volume":"57","author":"Richelson","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00008571-199902000-00003","article-title":"Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants","volume":"9","author":"Cravchik","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1176\/appi.psy.49.3.258_bib0165","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.tpj.6500378","article-title":"CYP2D6 genetic variations in healthy adults in psychiatric African American subjects: implications for clinical practice and genetic testing","volume":"6","author":"Cai","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1176\/appi.psy.49.3.258_bib0170","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000177546.34799.af","article-title":"Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness","volume":"25","author":"de Leon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","article-title":"Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response","volume":"32","author":"Arranz","year":"1998","journal-title":"Schizophr Res"},{"key":"10.1176\/appi.psy.49.3.258_bib0180","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","article-title":"Pharmacogenetic prediction of clozapine response","volume":"355","author":"Arranz","year":"2000","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.49.3.258_bib0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors: focus on newer-generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1176\/appi.psy.49.3.258_bib0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in-vitro and in-vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1176\/appi.psy.49.3.258_bib0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1176\/appi.psy.49.3.258_bib0200","first-page":"261","article-title":"Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors; clozapine occupies D4","volume":"7","author":"Seeman","year":"1992","journal-title":"Neuropsychopharmacology"},{"key":"10.1176\/appi.psy.49.3.258_bib0205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast association from the dopamine D2 receptor explain the action of atypical antipsychotics?","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0210","first-page":"390","article-title":"The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotics","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1176\/appi.psy.49.3.258_bib0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","article-title":"Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors","volume":"3","author":"Seeman","year":"1998","journal-title":"Mol Psychiatry"},{"issue":"10 suppl 11","key":"10.1176\/appi.psy.49.3.258_bib0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","article-title":"Atypical antipsychotics: matching receptor profile to individual patient\u2019s clinical profile","volume":"9","author":"Shayegan","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1176\/appi.psy.49.3.258_bib0225","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","article-title":"Treatment of psychosis in Parkinson\u2019s disease: safety considerations","volume":"26","author":"Fernandez","year":"2003","journal-title":"Drug Saf"},{"issue":"12 suppl","key":"10.1176\/appi.psy.49.3.258_bib0230","first-page":"S272","article-title":"Optimizing atypical antipsychotic treatment strategies in the elderly","volume":"52","author":"Katz","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1176\/appi.psy.49.3.258_bib0235","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archpsyc.1973.04200020023003","article-title":"An anatomy of schizophrenia?","volume":"29","author":"Stevens","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","article-title":"Mechanism of action of secondgeneration antipsychotic drugs in schizophrenia: insight for brainimaging studies","volume":"20","author":"Abi-Dargham","year":"2005","journal-title":"Eur Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nurx.2005.12.003","article-title":"How antipsychotics work: from receptors to reality","volume":"3","author":"Kapur","year":"2006","journal-title":"Neuro Rx"},{"issue":"12 suppl","key":"10.1176\/appi.psy.49.3.258_bib0250","first-page":"S258","article-title":"Pharmacology of antipsychotics in the elderly: a focus on atypicals","volume":"52","author":"Finkel","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1176\/appi.psy.49.3.258_bib0255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(01)00139-5","article-title":"Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs","volume":"90","author":"Joyce","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1176\/appi.psy.49.3.258_bib0260","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0024-3205(98)00148-9","article-title":"Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain","volume":"62","author":"Flietstra","year":"1998","journal-title":"Life Sci"},{"key":"10.1176\/appi.psy.49.3.258_bib0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004714-200302000-00002","article-title":"Optimizing limbicselective D2\/D3 receptor occupancy by risperidone: a[123I]-epidepride SPECT study","volume":"23","author":"Bressan","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0270","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1381612033391199","article-title":"Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders","volume":"9","author":"Luedtke","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1176\/appi.psy.49.3.258_bib0275","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0306-3623(76)90001-X","article-title":"Tolerance to phenothiazines in schizophrenic patients","volume":"7","author":"Malek-Ahmadi","year":"1976","journal-title":"Gen Pharmacol"},{"issue":"suppl 10","key":"10.1176\/appi.psy.49.3.258_bib0280","first-page":"55","article-title":"The relationship of pharmacology to side effects","volume":"58","author":"Casey","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0285","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4088\/JCP.v61n0312f","article-title":"Urinary incontinence with risperidone (letter)","volume":"61","author":"Agarwal","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4088\/JCP.v57n1109f","article-title":"Risperidone-induced ejaculatory and urinary dysfunction (letter)","volume":"57","author":"Madhusoodanan","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0295","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/01.ju.0000176460.62847.23","article-title":"Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction","volume":"174","author":"Ruggieri","year":"2005","journal-title":"J Urol"},{"key":"10.1176\/appi.psy.49.3.258_bib0300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2210-1-4","article-title":"Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats","volume":"1","author":"Vera","year":"2001","journal-title":"BMC Pharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/00926230701267829","article-title":"The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized, double-blind trial of risperidone vs. quetiapine","volume":"33","author":"Nakonezny","year":"2007","journal-title":"J Sex Marital Ther"},{"key":"10.1176\/appi.psy.49.3.258_bib0310","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(99)01000-9","article-title":"No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response","volume":"280","author":"Bolonna","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1176\/appi.psy.49.3.258_bib0315","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000026674","article-title":"No evidence for association of alpha1a adrenoceptor gene polymorphism and clozapine-induced urinary incontinence","volume":"42","author":"Hsu","year":"2000","journal-title":"Neuropsychobiology"},{"key":"10.1176\/appi.psy.49.3.258_bib0320","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0920-9964(00)00127-4","article-title":"Association study of polymorphisms of the \u03b12a-adrenoreceptor gene with schizophrenia and clozapine response","volume":"49","author":"Tsai","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1176\/appi.psy.49.3.258_bib0325","unstructured":"Remeron package insert : West Orange, NJ, Organon, 2002"},{"key":"10.1176\/appi.psy.49.3.258_bib0330","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.pnpbp.2005.03.019","article-title":"The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug response","volume":"29","author":"Reynolds","year":"2005","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0335","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"10.1176\/appi.psy.49.3.258_bib0340","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel antipsychotics: comparison of weight gain liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0345","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychoticinduced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1176\/appi.psy.49.3.258_bib0350","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","article-title":"Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism","volume":"359","author":"Reynolds","year":"2002","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.49.3.258_bib0355","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.jcp.0000203196.65710.2b","article-title":"Risperidone-related weight gain: genetic and nongenetic predictors","volume":"26","author":"Lane","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0360","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.163.4.451","article-title":"Ritanserin, a selective 5-HT2\/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled, double-blind trial","volume":"163","author":"Duinkerke","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0924-977X(91)90710-C","article-title":"Psychotropic effects of ritanserin, a selective S2 antagonist: an open study","volume":"1","author":"Strauss","year":"1991","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0370","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00002826-199012000-00003","article-title":"5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo","volume":"13","author":"Bersani","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0375","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-2007-1017385","article-title":"The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind, placebo-controlled study versus lorazepam","volume":"18","author":"Ceulemans","year":"1985","journal-title":"Pharmacopsychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0380","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1991.tb05533.x","article-title":"5-HT2 receptor antagonism in dysthymic disorder: a double-blind, placebo-controlled study with ritanserin","volume":"83","author":"Bersani","year":"1991","journal-title":"Acta Psychiatr Scand"},{"key":"10.1176\/appi.psy.49.3.258_bib0385","first-page":"230","article-title":"Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled, double-blind, international multicenter trial: Ritanserin in Alcoholism Work Group","volume":"23","author":"Wiesbeck","year":"1999","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1176\/appi.psy.49.3.258_bib0390","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic druginduced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1176\/appi.psy.49.3.258_bib0395","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-3057(03)00221-1","article-title":"Serotonergic and histaminergic mechanisms involved in intralipid drinking?","volume":"76","author":"Hartfield","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1176\/appi.psy.49.3.258_bib0400","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF00168630","article-title":"The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics","volume":"353","author":"Schlicker","year":"1996","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0405","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004714-200210000-00012","article-title":"Tolerance to daytime sedative effects of H1 antihistamines","volume":"22","author":"Richardson","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00041444-200209000-00009","article-title":"Genetic variant of the histamine1 receptor (glu349asp) and body weight change during clozapine treatment","volume":"12","author":"Hong","year":"2002","journal-title":"Psychiatr Genet"},{"key":"10.1176\/appi.psy.49.3.258_bib0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0304-3940(02)00178-7","article-title":"Investigation of promoter variants of the histamine-1 and -2 receptors in schizophrenia and clozapine response","volume":"333","author":"Mancama","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1176\/appi.psy.49.3.258_bib0420","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","volume":"51","author":"Newcomer","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0425","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00023210-200216020-00001","article-title":"Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?","volume":"16","author":"Henderson","year":"2002","journal-title":"CNS Drugs"},{"issue":"suppl 18","key":"10.1176\/appi.psy.49.3.258_bib0430","first-page":"36","article-title":"Abnormalities of glucose metabolism associated with atypical antipsychotic drugs","volume":"65","author":"Newcomer","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0435","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.biopsych.2006.03.014","article-title":"Serum-free fatty acids and glucose metabolism: insulin resistance in schizophrenia with chronic antipsychotics","volume":"60","author":"Wang","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1176\/appi.psy.49.3.258_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: a comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1176\/appi.psy.49.3.258_bib0445","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","article-title":"Atypical antipsychotic drugs and risk of ischemic stroke: population-based retrospective cohort study","volume":"330","author":"Gill","year":"2005","journal-title":"BMJ"},{"key":"10.1176\/appi.psy.49.3.258_bib0450","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0455","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","article-title":"Cardiovascular adverse effects of antipsychotic drugs","volume":"23","author":"Buckley","year":"2000","journal-title":"Drug Saf"},{"key":"10.1176\/appi.psy.49.3.258_bib0460","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00005344-200306000-00016","article-title":"Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current","volume":"41","author":"Drolet","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0465","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1017\/S1092852900000973","article-title":"Cardiovascular side effects of novel antipsychotics","volume":"6","author":"Gupta","year":"2001","journal-title":"CNS Spectrums"},{"key":"10.1176\/appi.psy.49.3.258_bib0470","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S1461145700001760","article-title":"Overdose profile of new antipsychotic agents","volume":"3","author":"Capel","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1176\/appi.psy.49.3.258_bib0475","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/026988110101500212","article-title":"Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine","volume":"15","author":"Wilton","year":"2001","journal-title":"J Psychopharmacol"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318208709381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318208709381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:26:08Z","timestamp":1758500768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318208709381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0033318208709381"],"URL":"https:\/\/doi.org\/10.1176\/appi.psy.49.3.258","relation":{},"ISSN":["0033-3182"],"issn-type":[{"type":"print","value":"0033-3182"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Preliminary Attempt to Personalize Risperidone Dosing Using Drug\u2013Drug Interactions and Genetics: Part I","name":"articletitle","label":"Article Title"},{"value":"Psychosomatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1176\/appi.psy.49.3.258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}